Keytruda Keeps Racking Up Approvals and Clinical Wins in ’23

First approved by the FDA in 2014, Keytruda is the undisputed cornerstone of Merck’s oncology portfolio. With 35 approvals across 16 types of cancer and two tumor-agnostic indications, the PD-1 inhibitor is projected to become the world’s top-selling drug by 2025.